Advanced in Agnosia

Bruno Dubois

Paris, FR 
Advanced in Agnosia
Paris, FR 
OverviewLocationsClinical Research

Overview

Bruno Dubois practices in Paris, France. Mr. Dubois is rated as an Advanced expert by MediFind in the treatment of Agnosia. His top areas of expertise are Alzheimer's Disease, Dementia, Memory Loss, and Frontotemporal Dementia.

His clinical research consists of co-authoring 355 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Agnosia.

Gender
Male

Locations

Paris, France
Other Locations
Toulouse, France
Bordeaux, France
Nantes, France
Pierre-la-treiche, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Memento-Plus : Long-term Follow-up of Cognitive and Functional Evolutions of Persons With Isolated Cognitive Complaints or Mild Cognitive Deficits
Enrollment Status: Completed
Publish Date: February 17, 2025
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
Enrollment Status: Completed
Publish Date: January 23, 2025
Intervention Type: Other
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Longitudinal Study of Brain Amyloid imaGing in MEMENTO
Enrollment Status: Completed
Publish Date: February 03, 2022
Intervention Type: Drug
Study Drugs: Flutemetamol, Florbetapir
Study Phase: Phase 3
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)
Enrollment Status: Terminated
Publish Date: March 31, 2020
View 7 Less Clinical Trials

353 Total Publications

Targeted serum metabolomic profiling and machine learning approach in Alzheimer's disease using the Alzheimer's disease diagnostics clinical study (ADDIA) cohort.
Targeted serum metabolomic profiling and machine learning approach in Alzheimer's disease using the Alzheimer's disease diagnostics clinical study (ADDIA) cohort.
Journal: Journal of Alzheimer's disease : JAD
Published: September 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Dubois's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 12 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile